Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Article in English | MEDLINE | ID: mdl-30455231

ABSTRACT

Signaling pathways play a key role in HIV-1 latency. In this study, we used the 24ST1NLESG cell line of HIV-1 latency to screen a library of structurally diverse, medicinally active, cell permeable kinase inhibitors, which target a wide range of signaling pathways, to identify inhibitors of HIV-1 latency reversal. The screen was carried out in the absence or presence of three mechanistically distinct latency-reversing agents (LRAs), namely, prostratin, panobinostat, and JQ-1. We identified inhibitors that only blocked the activity of a specific LRA, as well as inhibitors that blocked the activity of all LRAs. For example, we identified 12 inhibitors targeted toward protein kinase C or downstream kinases that blocked the activity of prostratin. We also identified 12 kinase inhibitors that blocked the reversal of HIV-1 latency irrespective of the LRA used in the screen. Of these, danusertib, an Aurora kinase inhibitor, and PF-3758309, a PAK4 inhibitor, were the most potent. The 50% inhibitory concentrations in the 24ST1NLESG cells ranged from 40 to 147 nM for danusertib (selectivity indices, >150) and from 0.1 to 1 nM for PF-3758309 (selectivity indices, >3,300). Both danusertib and PF-3758309 inhibited latency reversal in CD4+ T cells isolated from HIV-1-infected donors. Collectively, our study describes a chemical approach that can be applied to elucidate the role of signaling pathways involved in LRA activity or the maintenance of HIV-1 latency and also identifies inhibitors of latent HIV-1 reactivation that could be used with antiretroviral therapy to reduce residual viremia.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV-1/drug effects , HIV-1/pathogenicity , Benzamides/therapeutic use , CD4-Positive T-Lymphocytes/virology , Cell Line , HIV Infections/virology , Humans , Pyrazoles/therapeutic use , Pyrroles/therapeutic use , Signal Transduction/drug effects , Virus Activation/drug effects
2.
Nat Med ; 23(7): 885-889, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28553933

ABSTRACT

Although antiretroviral therapy can suppress HIV-1 infection to undetectable levels of plasma viremia, integrated latent HIV-1 genomes that encode replication-competent virus persist in resting CD4+ T cells. This latent HIV-1 reservoir represents a major barrier to a cure. Currently, there are substantial efforts to identify therapeutic approaches that will eliminate or reduce the size of this latent HIV-1 reservoir. In this regard, a sensitive assay that can accurately and rapidly quantify inducible, replication-competent latent HIV-1 from resting CD4+ T cells is essential for HIV-1 eradication studies. Here we describe a reporter cell-based assay to quantify inducible, replication-competent latent HIV-1. This assay has several advantages over existing technology in that it (i) is sensitive; (ii) requires only a small blood volume; (iii) is faster, less labor intensive, and less expensive; and (iv) can be readily adapted into a high-throughput format. Using this assay, we show that the size of the inducible latent HIV-1 reservoir in aviremic participants on therapy is approximately 70-fold larger than previous estimates.


Subject(s)
CD4-Positive T-Lymphocytes/virology , DNA, Viral/analysis , HIV Infections/virology , HIV-1/genetics , RNA, Viral/analysis , Viral Load/methods , Adult , Aged , Anti-HIV Agents/therapeutic use , Female , Fusion Proteins, gag-pol/genetics , HIV Infections/drug therapy , Humans , Male , Middle Aged , Virus Latency
3.
AIDS ; 31(5): 623-633, 2017 03 13.
Article in English | MEDLINE | ID: mdl-28005686

ABSTRACT

OBJECTIVE: HIV-1 viral proteins and host inflammatory factors have a direct role in neuronal toxicity in vitro; however, the contribution of these factors in vivo in HIV-1-associated neurocognitive disorder (HAND) is not fully understood. We applied novel Systems Biology approaches to identify specific cellular and viral factors and their related pathways that are associated with different stages of HAND. DESIGN: A cross-sectional study of individuals enrolled in the Multicenter AIDS Cohort Study including HIV-1-seronegative (N = 36) and HIV-1-seropositive individuals without neurocognitive symptoms (N = 16) or with mild neurocognitive disorder (MND) (N = 8) or HIV-associated dementia (HAD) (N = 16). METHODS: A systematic evaluation of global transcriptome of peripheral blood mononuclear cells (PBMCs) obtained from HIV-1-seronegative individuals and from HIV-1-positive men without neurocognitive symptoms, or MND or HAD was performed. RESULTS: MND and HAD were associated with specific changes in mRNA transcripts and microRNAs in PBMCs. Comparison of upstream regulators and TimePath analyses identified specific cellular factors associated with MND and HAD, whereas HIV-1 viral proteins played a greater role in HAD. In addition, expression of specific microRNAs - miR-let-7a, miR-124, miR-15a and others - were found to correlate with mRNA gene expression and may have a potential protective role in asymptomatic HIV-1-seropositive individuals by regulating cellular signal transduction pathways downstream of chemokines and cytokines. CONCLUSION: These results identify signature transcriptome changes in PBMCs associated with stages of HAND and shed light on the potential contribution of host cellular factors and viral proteins in HAND development.


Subject(s)
AIDS Dementia Complex/physiopathology , Gene Expression Profiling , HIV Infections/complications , HIV-1/pathogenicity , Host-Pathogen Interactions , Leukocytes, Mononuclear/physiology , Leukocytes, Mononuclear/virology , Cells, Cultured , Cross-Sectional Studies , Gene Regulatory Networks , Humans , Male , Systems Biology/methods
4.
Bioinformatics ; 32(12): i253-i261, 2016 06 15.
Article in English | MEDLINE | ID: mdl-27307624

ABSTRACT

MOTIVATION: Most methods for reconstructing response networks from high throughput data generate static models which cannot distinguish between early and late response stages. RESULTS: We present TimePath, a new method that integrates time series and static datasets to reconstruct dynamic models of host response to stimulus. TimePath uses an Integer Programming formulation to select a subset of pathways that, together, explain the observed dynamic responses. Applying TimePath to study human response to HIV-1 led to accurate reconstruction of several known regulatory and signaling pathways and to novel mechanistic insights. We experimentally validated several of TimePaths' predictions highlighting the usefulness of temporal models. AVAILABILITY AND IMPLEMENTATION: Data, Supplementary text and the TimePath software are available from http://sb.cs.cmu.edu/timepath CONTACT: zivbj@cs.cmu.edu SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.


Subject(s)
HIV-1 , Disease Progression , Gene Expression Profiling , Humans , Models, Theoretical , Software
5.
Retrovirology ; 12: 85, 2015 Oct 06.
Article in English | MEDLINE | ID: mdl-26438393

ABSTRACT

BACKGROUND: Latent HIV-1 reservoirs are identified as one of the major challenges to achieve HIV-1 cure. Currently available strategies are associated with wide variability in outcomes both in patients and CD4(+) T cell models. This underlines the critical need to develop innovative strategies to predict and recognize ways that could result in better reactivation and eventual elimination of latent HIV-1 reservoirs. RESULTS AND DISCUSSION: In this study, we combined genome wide transcriptome datasets post activation with Systems Biology approach (Signaling and Dynamic Regulatory Events Miner, SDREM analyses) to reconstruct a dynamic signaling and regulatory network involved in reactivation mediated by specific activators using a latent cell line. This approach identified several critical regulators for each treatment, which were confirmed in follow-up validation studies using small molecule inhibitors. Results indicate that signaling pathways involving JNK and related factors as predicted by SDREM are essential for virus reactivation by suberoylanilide hydroxamic acid. ERK1/2 and NF-κB pathways have the foremost role in reactivation with prostratin and TNF-α, respectively. JAK-STAT pathway has a central role in HIV-1 transcription. Additional evaluation, using other latent J-Lat cell clones and primary T cell model, also confirmed that many of the cellular factors associated with latency reversing agents are similar, though minor differences are identified. JAK-STAT and NF-κB related pathways are critical for reversal of HIV-1 latency in primary resting T cells. CONCLUSION: These results validate our combinatorial approach to predict the regulatory cellular factors and pathways responsible for HIV-1 reactivation in latent HIV-1 harboring cell line models. JAK-STAT have a role in reversal of latency in all the HIV-1 latency models tested, including primary CD4(+) T cells, with additional cellular pathways such as NF-κB, JNK and ERK 1/2 that may have complementary role in reversal of HIV-1 latency.


Subject(s)
HIV-1/physiology , Virus Activation/drug effects , Virus Activation/genetics , Virus Latency/genetics , CD4-Positive T-Lymphocytes/physiology , CD4-Positive T-Lymphocytes/virology , Gene Expression Profiling/methods , Gene Expression Regulation, Viral/drug effects , HIV-1/drug effects , HIV-1/genetics , Humans , Hydroxamic Acids/pharmacology , Jurkat Cells , Male , Phorbol Esters/pharmacology , Signal Transduction/drug effects , Systems Biology/methods , Tumor Necrosis Factor-alpha , Virus Latency/drug effects , Vorinostat
6.
J Virol ; 85(10): 4888-97, 2011 May.
Article in English | MEDLINE | ID: mdl-21325415

ABSTRACT

Xenotropic murine leukemia virus-related virus (XMRV) is a gammaretrovirus recently isolated from human prostate cancer and peripheral blood mononuclear cells (PBMCs) of patients with chronic fatigue syndrome (CFS). We and others have shown that host restriction factors APOBEC3G (A3G) and APOBEC3F (A3F), which are expressed in human PBMCs, inhibit XMRV in transient-transfection assays involving a single cycle of viral replication. However, the recovery of infectious XMRV from human PBMCs suggested that XMRV can replicate in these cells despite the expression of APOBEC3 proteins. To determine whether XMRV can replicate and spread in cultured PBMCs even though it can be inhibited by A3G/A3F, we infected phytohemagglutinin-activated human PBMCs and A3G/A3F-positive and -negative cell lines (CEM and CEM-SS, respectively) with different amounts of XMRV and monitored virus production by using quantitative real-time PCR. We found that XMRV efficiently replicated in CEM-SS cells and viral production increased by >4,000-fold, but there was only a modest increase in viral production from CEM cells (<14-fold) and a decrease in activated PBMCs, indicating little or no replication and spread of XMRV. However, infectious XMRV could be recovered from the infected PBMCs by cocultivation with a canine indicator cell line, and we observed hypermutation of XMRV genomes in PBMCs. Thus, PBMCs can potentially act as a source of infectious XMRV for spread to cells that express low levels of host restriction factors. Overall, these results suggest that hypermutation of XMRV in human PBMCs constitutes one of the blocks to replication and spread of XMRV. Furthermore, hypermutation of XMRV proviruses at GG dinucleotides may be a useful and reliable indicator of human PBMC infection.


Subject(s)
Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/virology , Virus Replication , Xenotropic murine leukemia virus-related virus/immunology , Xenotropic murine leukemia virus-related virus/pathogenicity , APOBEC-3G Deaminase , Cells, Cultured , Cytidine Deaminase/genetics , Cytidine Deaminase/immunology , Cytosine Deaminase/genetics , Cytosine Deaminase/immunology , Humans
7.
J Virol ; 84(19): 10241-53, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20668078

ABSTRACT

Recent studies have shown that APOBEC3G (A3G), a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) replication, is localized to cytoplasmic mRNA-processing bodies (P bodies). However, the functional relevance of A3G colocalization with P body marker proteins has not been established. To explore the relationship between HIV-1, A3G, and P bodies, we analyzed the effects of overexpression of P body marker proteins Mov10, DCP1a, and DCP2 on HIV-1 replication. Our results show that overexpression of Mov10, a putative RNA helicase that was previously reported to belong to the DExD superfamily and was recently reported to belong to the Upf1-like group of helicases, but not the decapping enzymes DCP1a and DCP2, leads to potent inhibition of HIV-1 replication at multiple stages. Mov10 overexpression in the virus producer cells resulted in reductions in the steady-state levels of the HIV-1 Gag protein and virus production; Mov10 was efficiently incorporated into virions and reduced virus infectivity, in part by inhibiting reverse transcription. In addition, A3G and Mov10 overexpression reduced proteolytic processing of HIV-1 Gag. The inhibitory effects of A3G and Mov10 were additive, implying a lack of functional interaction between the two inhibitors. Small interfering RNA (siRNA)-mediated knockdown of endogenous Mov10 by 80% resulted in a 2-fold reduction in virus production but no discernible impact on the infectivity of the viruses after normalization for the p24 input, suggesting that endogenous Mov10 was not required for viral infectivity. Overall, these results show that Mov10 can potently inhibit HIV-1 replication at multiple stages.


Subject(s)
HIV-1/physiology , RNA Helicases/physiology , Virus Replication/physiology , APOBEC-3G Deaminase , Cell Line , Cytidine Deaminase/physiology , Cytoplasmic Structures/physiology , Cytoplasmic Structures/virology , Gene Knockdown Techniques , Green Fluorescent Proteins/genetics , HIV-1/genetics , HIV-1/pathogenicity , HeLa Cells , Host-Pathogen Interactions/genetics , Host-Pathogen Interactions/physiology , Humans , Protein Processing, Post-Translational , RNA Helicases/antagonists & inhibitors , RNA Helicases/genetics , RNA Processing, Post-Transcriptional , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/genetics , RNA, Viral/genetics , RNA, Viral/metabolism , Virus Assembly , gag Gene Products, Human Immunodeficiency Virus/physiology
8.
Virol J ; 7: 119, 2010 Jun 07.
Article in English | MEDLINE | ID: mdl-20529298

ABSTRACT

HIV-1 Vpr, a nonstructural viral protein associated with virus particles, has a positive role in the efficient transport of PIC into the nucleus of non-dividing target cells and enhances virus replication in primary T cells. Vpr is a 96 amino acid protein and the structure by NMR shows three helical domains. Vpr has been shown to exist as dimers and higher order oligomers. Considering the multifunctional nature of Vpr, the contribution of distinct helical domains to the dimer/oligomer structure of Vpr and the relevance of this feature to its functions are not clear. To address this, we have utilized molecular modeling approaches to identify putative models of oligomerization. The predicted interface residues were subjected to site-directed mutagenesis and evaluated their role in intermolecular interaction and virion incorporation. The interaction between Vpr molecules was monitored by Bimolecular Fluorescence complementation (BiFC) method. The results show that Vpr forms oligomers in live cells and residues in helical domains play critical roles in oligomerization. Interestingly, Vpr molecules defective in oligomerization also fail to incorporate into the virus particles. Based on the data, we suggest that oligomerization of Vpr is essential for virion incorporation property and may also have a role in the events associated with virus infection.


Subject(s)
HIV-1/metabolism , Virion/metabolism , vpr Gene Products, Human Immunodeficiency Virus/chemistry , vpr Gene Products, Human Immunodeficiency Virus/metabolism , Amino Acid Sequence , Cell Line , HIV-1/chemistry , HIV-1/genetics , Humans , Molecular Conformation , Molecular Sequence Data , Protein Structure, Tertiary , Sequence Alignment , Virion/chemistry , Virion/genetics , vpr Gene Products, Human Immunodeficiency Virus/genetics
9.
J Virol ; 84(11): 5719-29, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20335265

ABSTRACT

Xenotropic murine leukemia virus-related virus (XMRV), a gammaretrovirus, has been isolated from human prostate cancer tissue and from activated CD4(+) T cells and B cells of patients with chronic fatigue syndrome, suggesting an association between XMRV infection and these two diseases. Since APOBEC3G (A3G) and APOBEC3F (A3F), which are potent inhibitors of murine leukemia virus and Vif-deficient human immunodeficiency virus type 1 (HIV-1), are expressed in human CD4(+) T cells and B cells, we sought to determine how XMRV evades suppression of replication by APOBEC3 proteins. We found that expression of A3G, A3F, or murine A3 in virus-producing cells resulted in their virion incorporation, inhibition of XMRV replication, and G-to-A hypermutation of the viral DNA with all three APOBEC3 proteins. Quantitation of A3G and A3F mRNAs indicated that, compared to the human T-cell lines CEM and H9, prostate cell lines LNCaP and DU145 exhibited 50% lower A3F mRNA levels, whereas A3G expression in 22Rv1, LNCaP, and DU145 cells was nearly undetectable. XMRV proviral genomes in LNCaP and DU145 cells were hypermutated at low frequency with mutation patterns consistent with A3F activity. XMRV proviral genomes were extensively hypermutated upon replication in A3G/A3F-positive T cells (CEM and H9), but not in A3G/A3F-negative cells (CEM-SS). We also observed that XMRV replication was susceptible to the nucleoside reverse transcriptase (RT) inhibitors zidovudine (AZT) and tenofovir and the integrase inhibitor raltegravir. In summary, the establishment of XMRV infection in patients may be dependent on infection of A3G/A3F-deficient cells, and cells expressing low levels of A3G/A3F, such as prostate cancer cells, may be ideal producers of infectious XMRV. Furthermore, the anti-HIV-1 drugs AZT, tenofovir, and raltegravir may be useful for treatment of XMRV infection.


Subject(s)
Antiviral Agents/pharmacology , Cytidine Deaminase/immunology , Gammaretrovirus/immunology , Leukemia Virus, Murine/immunology , Prostatic Neoplasms/virology , Retroviridae Infections/immunology , Tumor Virus Infections/immunology , Adenine/analogs & derivatives , Adenine/pharmacology , Animals , Cell Line, Tumor , Cytidine Deaminase/genetics , Humans , Male , Mice , Mutation , Organophosphonates/pharmacology , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/pathology , Pyrrolidinones/pharmacology , Raltegravir Potassium , Retroviridae Infections/drug therapy , Tenofovir , Tumor Virus Infections/drug therapy , Zidovudine/pharmacology
10.
PLoS One ; 4(10): e7470, 2009 Oct 15.
Article in English | MEDLINE | ID: mdl-19829715

ABSTRACT

Dendritic cells (DC) play a pivotal role in transmission and dissemination of HIV-1. Earlier studies reported that DC present at the site of infection trap virus particles via DC-SIGN and transfer the virus to the interacting naïve T cells. This prompted us to ask the question whether DC could acquire virus from infected T cells during DC-T cell interaction. To address this, we investigated the likely transfer of virus from HIV-1 infected T cells to DC and the underlying mechanisms involved. Results indicate that DC acquire virus from infected T cells via antigen uptake mechanism and this results in infection of DC with expression of proteins directed by viral DNA. Further studies with HIV-1 lacking the Env protein also resulted in infection of DC. The use of antibodies against DC-SIGN and DC-SIGN-R ruled out a role for receptor in the infection of DC. Additional data show that DC infection is directly correlated with the ability of DC to take up antigen from infected T cells. Overall, these studies provide evidence to suggest that HIV-1, besides infecting immune cells, also utilizes immunological mechanism(s) to acquire and disseminate virus.


Subject(s)
Dendritic Cells/virology , HIV Infections/metabolism , HIV Infections/virology , HIV-1/metabolism , T-Lymphocytes/virology , CD4-Positive T-Lymphocytes/virology , Cell Adhesion Molecules/metabolism , Green Fluorescent Proteins/chemistry , Humans , Jurkat Cells , Lectins, C-Type/metabolism , Leukocytes, Mononuclear/cytology , Mannose Receptor , Mannose-Binding Lectins/metabolism , Microscopy, Fluorescence/methods , Phenotype , Plasmids/metabolism , Receptors, Cell Surface/metabolism , T-Lymphocytes/metabolism
11.
Curr HIV Res ; 7(2): 169-77, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19275586

ABSTRACT

HIV-1 exploits the cellular machinery to replicate in the host cells by targeting a wide range of host factors at different stages of its life cycle. HIV-1 also induces detrimental effects in the infected and uninfected bystander cells resulting in dysregulation including interference in immune effector functions. The latter is specifically linked to the immune evasion strategies of the virus. In addition to the essential roles of structural proteins (Gag, Pol & Env), HIV-1 encoded auxiliary proteins such as Nef, Vif, Vpu, and Vpr through their interaction with the host cellular partners facilitate viral replication and dissemination. HIV-1 Vpr, a virion-associated molecule, has been implicated to play a role in the early events in virus life cycle. Vpr is a pleiotropic protein that exerts a range of effects including inhibition of cell proliferation, induction of apoptosis and modulation of a number of immune molecules. These functions could be in part responsible for Vpr induced immune evasion and virus replication. Appreciating this view is the genetic variation in vpr gene reflected in the form of polymorphisms at the amino acid level that may contribute to the potential CTL escape of the virus. It is likely that Vpr mediated dysregulation of host immune response contributes, in part, to the progression of disease. This review focuses on the recent advances regarding HIV-1 Vpr mediated immunopathogenesis and the mechanistic insight from in vitro and in vivo studies.


Subject(s)
HIV-1/pathogenicity , Virulence Factors/physiology , vpr Gene Products, Human Immunodeficiency Virus/physiology , HIV-1/immunology , Humans , Immune Tolerance
12.
J Virol ; 82(14): 7189-200, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18417583

ABSTRACT

Human immunodeficiency virus type 1 (HIV-1) infection has been implicated in impairing various aspects of NK cell function in viremic condition, and several viral factors contribute to these defects. Here, we evaluated the effect of HIV-1 Vpr on NK cell cytolytic function and cytokine (gamma interferon [IFN-gamma]) production in the context of infection and exposure. Our data indicate that NK cells derived from a peripheral blood mononuclear cell culture infected in vitro with HIV-1 vpr(+) virus or exposed to recombinant Vpr protein exhibited reduced target cell killing in conjunction with diminished expression of CD107a and reduced IFN-gamma production compared to their Vpr-negative counterparts. This Vpr-induced NK cell defect is in part through differential regulation of interleukin-12 and transforming growth factor beta production by the infected target cells and concomitant activation of Smad3 signaling pathway. Collectively, these results illustrate the ability of Vpr to impair NK cell-mediated innate immune functions indirectly by dysregulating multiple cytokines in the infected target cells, thus increasing disease severity and affecting the final outcome in HIV-1 infection.


Subject(s)
Cytokines/biosynthesis , HIV-1/immunology , Killer Cells, Natural/immunology , vpr Gene Products, Human Immunodeficiency Virus/immunology , Cells, Cultured , Cytokines/immunology , Cytotoxicity Tests, Immunologic , Humans , Killer Cells, Natural/virology , Leukocytes, Mononuclear/immunology , Lysosomal-Associated Membrane Protein 1/biosynthesis
13.
Virology ; 376(1): 140-53, 2008 Jun 20.
Article in English | MEDLINE | ID: mdl-18440040

ABSTRACT

Programmed Death-1 (PD-1), a member of T cell costimulatory molecules is expressed in high levels on antigen specific T cells during chronic viral infection, whereas PD-1 expression in the context of HIV-1 infected CD4+ T cells is not known. Here we report that productively infected CD4+ T cells lose PD-1, whereas bystander cells were unaffected. Additionally, p24+/PD-1 negative cells are less susceptible to apoptosis compared to bystander cells in the same infected milieu. Similar results were observed in vivo, as infected T cells isolated from HIV-1+ individuals have significantly low level of PD-1 and the observed loss of PD-1 in vivo is independent of viral load, CD4 count, and/or antiviral treatment. Together these results indicate that productively infected cells are resistant to early apoptosis by downregulating PD-1, whereas PD-1 enhances the susceptibility of effector T cells to apoptosis suggesting a dual role for PD-1 during HIV-1 infection.


Subject(s)
Apoptosis Regulatory Proteins/antagonists & inhibitors , Apoptosis , CD4-Positive T-Lymphocytes/virology , HIV-1/immunology , Anti-Retroviral Agents/therapeutic use , Antigens, CD , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/chemistry , HIV Core Protein p24/analysis , HIV Infections/drug therapy , HIV Infections/immunology , Humans , Programmed Cell Death 1 Receptor , Viral Load
14.
J Virol ; 81(14): 7388-99, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17475642

ABSTRACT

Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) plays a crucial role in viral replication and pathogenesis by inducing cell cycle arrest, apoptosis, translocation of preintegration complex, potentiation of glucocorticoid action, impairment of dendritic cell (DC) maturation, and T-cell activation. Recent studies involving the direct effects of Vpr on DCs and T cells indicated that HIV-1 containing Vpr selectively impairs phenotypic maturation, cytokine network, and antigen presentation in DCs and dysregulates costimulatory molecules and cytokine production in T cells. Here, we have further investigated the indirect effect of HIV-1 Vpr(+) virus-infected DCs on the bystander CD8(+) T-cell population. Our results indicate that HIV-1 Vpr(+) virus-infected DCs dysregulate CD8(+) T-cell proliferation and induce apoptosis. Vpr-containing virus-infected DC-mediated CD8(+) T-cell killing occurred in part through enhanced tumor necrosis factor alpha production by infected DCs and subsequent induction of death receptor signaling and activation of the caspase 8-dependent pathway in CD8(+) T cells. Collectively, these results provide evidence that Vpr could be one of the important contributors to the host immune escape by HIV-1 through its ability to dysregulate both directly and indirectly the DC biology and T-cell functions.


Subject(s)
Apoptosis/immunology , CD8-Positive T-Lymphocytes/immunology , Dendritic Cells/immunology , HIV-1/physiology , T-Lymphocytes/cytology , Tumor Necrosis Factor-alpha/metabolism , Up-Regulation , Cells, Cultured , Humans , Reverse Transcriptase Polymerase Chain Reaction , STAT1 Transcription Factor/metabolism , Signal Transduction , Tumor Necrosis Factor-alpha/biosynthesis
15.
Virology ; 358(2): 347-56, 2007 Feb 20.
Article in English | MEDLINE | ID: mdl-17023015

ABSTRACT

Human immunodeficiency virus type 1 (HIV-1) viral proteins disrupt the normal host cellular immune pathways thus exploiting the cellular machinery for replication, survival and to escape host immune attack. Here we evaluated the direct effects of HIV-1 Vpr-mediated immune modulation of infected T cells. Vpr specifically downregulated the expression of CD28 and increased the expression of CTLA-4, whereas no significant difference in the expression of CD25 and HLA-DR was observed. Interferon gamma (IFN-gamma) production in T cells was evaluated as a measure of the downstream effector functions. Results indicate that Vpr significantly inhibited IFN-gamma production and this may, in part, due to Vpr's ability to inhibit the nuclear translocation of NF-kappaB, and its transcriptional regulation. Together these results support that HIV-1 Vpr selectively dysregulates the immune functions at multiple levels and exerts its inhibitory effects in the presence of other viral proteins.


Subject(s)
Gene Products, vpr/immunology , HIV Infections/immunology , HIV Infections/metabolism , HIV-1 , T-Lymphocytes/immunology , Antigens, CD/metabolism , Antigens, Differentiation/metabolism , CD28 Antigens/metabolism , CTLA-4 Antigen , Cell Nucleus/metabolism , Cells, Cultured , Humans , Interferon-gamma/biosynthesis , Leukocytes, Mononuclear , Lymphocyte Activation , NF-kappa B/metabolism , vpr Gene Products, Human Immunodeficiency Virus
16.
Antiviral Res ; 72(3): 224-32, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16889838

ABSTRACT

The HIV-1 viral protein R, Vpr, increases virus replication in T cells and is necessary for the optimal infection of primary monocytes/macrophages and other non-dividing cells. Vpr interacts with the cellular glucocorticoid receptor (GR) and transactivates the HIV-1 LTR through glucocorticoid response element (GRE), an event that can be blocked by the GR antagonist, mifepristone. Results demonstrated that Vpr-induced transactivation of the HIV-1 LTR was inhibited by mifepristone in a dose-dependent manner by >60% at a 10 microM concentration. Infectivity assays using X4 and R5 viruses demonstrated antiviral effects on a dose-dependent regimen of mifepristone. The effects of mifepristone were also tested in latently infected cells that could be activated with extracellular Vpr protein and results indicated specific inhibition of virus reactivation in the presence of this antagonist.


Subject(s)
Anti-HIV Agents/pharmacology , Gene Expression Regulation, Viral/drug effects , Gene Products, vpr/metabolism , HIV-1/drug effects , Mifepristone/pharmacology , Receptors, Glucocorticoid/metabolism , Virus Replication/drug effects , Cell Line , Cells, Cultured , Dose-Response Relationship, Drug , HIV Core Protein p24/biosynthesis , HIV Long Terminal Repeat/genetics , HIV Long Terminal Repeat/physiology , HIV-1/physiology , HeLa Cells , Humans , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/virology , Macrophages/cytology , Macrophages/drug effects , Macrophages/virology , Promoter Regions, Genetic , Transcriptional Activation , Virus Activation , Virus Latency , vpr Gene Products, Human Immunodeficiency Virus
SELECTION OF CITATIONS
SEARCH DETAIL
...